Letter abstract
Nature Medicine 15, 788 - 793 (2009)
Published online: 28 June 2009 | doi:10.1038/nm.1980
Activation of kinin receptor B1 limits encephalitogenic T lymphocyte recruitment to the central nervous system
Ulf Schulze-Topphoff1, Alexandre Prat2, Timour Prozorovski1,6, Volker Siffrin1, Magdalena Paterka1, Josephine Herz1, Ivo Bendix1, Igal Ifergan2, Ines Schadock3, Marcelo A Mori3, Jack Van Horssen4, Friederike Schröter1,6, Alina Smorodchenko1, May Htwe Han5, Michael Bader3, Lawrence Steinman5, Orhan Aktas1,6,7 & Frauke Zipp1,7
Previous proteomic and transcriptional analyses of multiple sclerosis lesions1, 2, 3 revealed modulation of the renin-angiotensin and the opposing kallikrein-kinin pathways. Here we identify kinin receptor B1 (Bdkrb1) as a specific modulator of immune cell entry into the central nervous system (CNS). We demonstrate that the Bdkrb1 agonist R838 (Sar-[D-Phe]des-Arg9-bradykinin) markedly decreases the clinical symptoms of experimental autoimmune encephalomyelitis (EAE) in SJL mice4, 5, 6, whereas the Bdkrb1 antagonist R715 (Ac-Lys-[D-
Nal7, Ile8]des-Arg9-bradykinin) resulted in earlier onset and greater severity of the disease. Bdkrb1-deficient (Bdkrb1-/-) C57BL/6 mice7 immunized with a myelin oligodendrocyte glycoprotein fragment, MOG35–55, showed more severe disease with enhanced CNS-immune cell infiltration. The same held true for mixed bone marrow–chimeric mice reconstituted with Bdkrb1-/- T lymphocytes, which showed enhanced T helper type 17 (TH17) cell invasion into the CNS. Pharmacological modulation of Bdkrb1 revealed that in vitro migration of human TH17 lymphocytes across blood-brain barrier endothelium is regulated by this receptor. Taken together, these results suggest that the kallikrein-kinin system is involved in the regulation of CNS inflammation, limiting encephalitogenic T lymphocyte infiltration into the CNS, and provide evidence that Bdkrb1 could be a new target for the treatment of chronic inflammatory diseases such as multiple sclerosis.
- Cecilie Vogt Klinik, Charité–University Hospital Berlin, Max Delbrueck Center for Molecular Medicine and NeuroCure Research Center, Berlin, Germany.
- Neuroimmunology Research Laboratory, Centre Hospitalier de l'Université de Montréal, Montréal, Québéc, Canada.
- Max Delbrueck Center for Molecular Medicine, Berlin, Germany.
- Department of Molecular Cell Biology and Immunology, Vrije Universiteit University Medical Center, Amsterdam, The Netherlands.
- Department of Neurology and Neurological Sciences, Stanford University, Stanford, California, USA.
- Current addresses: Molecular Neurology Research Group, Department of Neurology, Heinrich-Heine-University Duesseldorf, Germany (T.P., O.A.); Institute of Biochemistry, Charité–University Hospital Berlin, Germany (F.S.).
- These authors contributed equally to this work.
Correspondence to: Frauke Zipp1,7 e-mail: frauke.zipp@charite.de
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
The fine line between autoimmune and allergic encephalomyelitisNature Immunology News and Views (01 Mar 2001)
Inflammatory disease Assault on the guardianNature News and Views (26 Jul 2007)
See all 3 matches for News And ViewsRESEARCH
Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammationNature Medicine Article (01 Apr 2007)
Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammationNature Medicine Article (01 Apr 2007)
See all 57 matches for Research
